Enterolactone has stronger effects than enterodiol on ovarian cancer
Abstract Background Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-017-0346-z |